Meeting
2013 ASCO Quality Care Symposium
Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).
Authors
Matti S. Aapro
Clinique de Genolier, Genolier, Switzerland
Matti S. Aapro, Giorgia Rossi, Giada Rizzi, Maria Elisa Borroni, Norman G. Nagl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Science of Quality
Track
Science of Quality,Health Reform: Implications for Costs and Quality ,Practice of Quality
Sub Track
Quality Improvement
Citation
J Clin Oncol 31, 2013 (suppl 31; abstr 66)
Abstract #
66
Poster Bd #
D4
Abstract Disclosures
Similar Posters
Poster
2014 Palliative and Supportive Care in Oncology Symposium
Evaluation of nausea control with NEPA, a novel oral combination antiemetic.
First Author: Snezana Bosnjak
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
First Author: Daniel Powers
Poster
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).
First Author: Paul Joseph Hesketh
Poster
2014 ASCO Annual Meeting
Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC).
First Author: Ian D. Schnadig